Adicet Bio
ACET
96 hedge funds and large institutions have $177M invested in Adicet Bio in 2024 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 39 increasing their positions, 14 reducing their positions, and 11 closing their positions.
182% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 11
179% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 14
158% more capital invested
Capital invested by funds: $68.3M → $177M (+$108M)
68% more call options, than puts
Call options by funds: $109K | Put options by funds: $65K
26% more funds holding
Funds holding: 76 → 96 (+20)
0.48% more ownership
Funds ownership: 5.24% → 5.72% (+0.48%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$19.5M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$16M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$14.3M |
| 4 |
Goldman Sachs
New York
|
+$10.3M |
| 5 |
O
OrbiMed
New York
|
+$8.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
-$4.8M |
| 2 |
Morgan Stanley
New York
|
-$3.96M |
| 3 |
JJ
Johnson & Johnson
New Brunswick,
New Jersey
|
-$838K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$528K |
| 5 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
-$144K |
ACET Hedge Fund Activity: Q1 2024 in Review
96 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q1 2024, worth a combined $177M — up 158% from $68.3M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ACET positions and 11 closed out — a net gain of 20 holders — while 39 added to existing stakes and 14 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $19.5M. The largest seller was Cowen and Company, cutting an estimated $4.8M.
- 96 institutional investors held Adicet Bio (ACET) as of Q1 2024, up from 76 in Q4 2023.
- Funds reported $177M of Adicet Bio stock for Q1 2024, up 158% quarter-over-quarter.
- 31 funds opened new Adicet Bio positions in Q1 2024 and 11 closed out, a net change of +20 holders.
- The largest Adicet Bio buyer in Q1 2024 was RA Capital Management, an estimated $19.5M added.
- The largest Adicet Bio seller in Q1 2024 was Cowen and Company, an estimated $4.8M sold.
Based on aggregated 13F filings for Q1 2024.